Investigation of Potential Action on Behalf of Former Emisphere Technologies, Inc. (”Emisphere”) (OTC: EMIS) Shareholders
Emisphere is a pharmaceutical and drug delivery company, which, through its partnerships with leading life science companies including Novo Nordisk A/S (NYSE: NVO), develops new formulations of existing products, as well as new chemical entities, using Emisphere’s Eligen technology, a proprietary drug delivery mechanism.
Kessler Topaz Meltzer & Check, LLP (“Kessler Topaz”) is investigating potential claims on behalf of former Emisphere Technologies, Inc. shareholders related to its acquisition by Novo Nordisk A/S on December 8, 2020, wherein Emisphere shareholders received $7.83 cash for each share of Emisphere owned. Kessler Topaz is seeking to determine whether the process that led to the acquisition was fair and whether the consideration paid to Emisphere shareholders undervalued the Company.
If you held shares of Emisphere Technologies, Inc. (OTC: EMIS) through the merger with Novo Nordisk A/S, and would like to learn more about our investigation, please fill out our online form or contact James Maro at (484) 270-1453 or Adrienne Bell at (484) 270-1435 or toll free at (844)-887-9500; or via email at info@ktmc.com.
CONTACT: Kessler Topaz Meltzer & Check, LLP James Maro, Esq. or Adrienne Bell, Esq. 280 King of Prussia Road Radnor, PA 19087 1-844-887-9500 (toll free) Or by e-mail at info@ktmc.com